UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 14, 2013
TETRA TECH, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
0-19655 |
|
95-4148514 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
of incorporation) |
|
File Number) |
|
Identification Number) |
3475 East Foothill Boulevard, Pasadena, California 91107
(Address of principal executive office, including zip code)
(626) 351-4664
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
Dr. Kimberly E. Ritrievi has been elected to the Board of Directors of Tetra Tech, Inc. (the Registrant), effective November 14, 2013, to serve until the next Annual Meeting of Stockholders or until her successor has been duly chosen and qualified. Dr. Ritrievi filled a vacancy on the Board, and the Board now consists of nine members, including Dr. Ritrievi. Pursuant to the Registrants compensation policy for non-employee directors, Dr. Ritrievi received in connection with her election (i) a pro rata portion of the annual cash retainer for 2013, and (ii) a non-qualified option to purchase 8,000 shares of common stock under the Registrants 2005 Equity Incentive Plan at $28.68 per share, the fair market value (closing price) of a share of common stock on the grant date.
Dr. Ritrievi is currently President of The Ritrievi Group LLC where she has advised technology and chemical companies on financial strategies. From 2001 to 2004 she served as Co-Director of Americas Investment Research at Goldman, Sachs & Co. Prior to that she was a Specialty Chemicals Analyst at Goldman, Sachs & Co., Credit Suisse First Boston, Lehman Brothers and Paine Webber (now UBS Wealth Management). Dr. Ritrievi started her career as a process development engineer at ARCO Chemical. She received her doctorate in Chemical Engineering from the Massachusetts Institute of Technology (MIT), and holds a masters degree in Management from the MIT Sloan School of Management. Dr. Ritrievi continues to serve on advisory boards at Princeton University, Harvard University, and MIT.
A copy of the press release issued by the Registrant concerning the foregoing is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 |
|
Press Release dated November 15, 2013 regarding the election of Kimberly E. Ritrievi to the Registrants Board of Directors. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
TETRA TECH, INC. | ||
|
|
| ||
|
|
| ||
Date: |
November 15, 2013 |
|
By: |
/s/ DAN L. BATRACK |
|
|
|
Dan L. Batrack | |
|
|
|
Chairman and Chief Executive Officer | |
Exhibit 99.1
November 15, 2013
Tetra Tech Elects Dr. Kimberly Ritrievi as New Board Member
Pasadena, California. Tetra Tech, Inc. (NASDAQ: TTEK) announced today that the Board of Directors has elected Kimberly E. Ritrievi to serve as a new director. Tetra Techs Board now totals nine members and includes eight outside directors.
Dr. Ritrievi is currently President of The Ritrievi Group LLC where she has advised technology and chemical companies on financial strategies. From 2001 to 2004 she served as Co-Director of Americas Investment Research at Goldman, Sachs & Co. Prior to that she was a Specialty Chemicals Analyst at Goldman, Sachs & Co., Credit Suisse First Boston, Lehman Brothers and Paine Webber (now UBS Wealth Management). Dr. Ritrievi started her career as a process development engineer at ARCO Chemical. She received her doctorate in Chemical Engineering from the Massachusetts Institute of Technology (MIT), and holds a masters degree in Management from the MIT Sloan School of Management. Dr. Ritrievi continues to serve on advisory boards at Princeton University, Harvard University, and MIT.
Tetra Techs Chairman and CEO, Dan Batrack said, We are pleased to welcome Dr. Ritrievi to our Board of Directors. Kim brings more than 25 years of experience in financial analysis, and a technical and educational background that enables her to make significant contributions to the Companys strategy. We look forward to working with her on the Board.
About Tetra Tech (www.tetratech.com)
Tetra Tech is a leading provider of consulting, engineering, program management, construction management, and technical services. The Company supports government and commercial clients by providing innovative solutions to complex problems focused on water, environment, energy, infrastructure, and natural resources. With more than 14,000 staff worldwide, Tetra Techs capabilities span the entire project life cycle.
CONTACTS:
Jim Wu, Investor Relations
Charlie MacPherson, Media & Public Relations
(626) 470-2844
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent managements best judgment as to what may occur in the future. However, Tetra Techs actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions (Future Factors), and may differ materially from what is expressed. For a description of Future Factors that could cause actual results to differ materially from such forward-looking statements, see the discussion under the section Risk Factors included in the Companys Form 10-K and 10-Q filings with the Securities and Exchange Commission.